Watson Pharmaceuticals, Inc.
WPI today confirmed that its subsidiary, Watson Laboratories, Inc.,
filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug
Administration (FDA) seeking approval to market Norethindrone Acetate/Ethinyl
Estradiol and Ethinyl Estradiol and Ferrous Fumarate Tablets,1 mg/0.01 mg
and 0.01 mg and 75 mg. Watson's ANDA product is a generic version of Warner
Chilcott Company LLC's Lo Loestrin^® Fe which is indicated for use by women to
prevent pregnancy.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in